Aravive (Aravive) 3-Year Revenue Growth Rate : -15.10% (As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Aravive 3-Year Revenue Growth Rate?

Aravive's Revenue per Share for the three months ended in Sep. 2023 was $0.04.

During the past 12 months, Aravive's average Revenue per Share Growth Rate was -70.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was -15.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was -34.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 11 years, the highest 3-Year average Revenue per Share Growth Rate of Aravive was 24.80% per year. The lowest was -62.50% per year. And the median was -15.10% per year.

Competitive Comparison of Aravive's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Aravive's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aravive's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aravive's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Aravive's 3-Year Revenue Growth Rate falls into.

Aravive 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Aravive (NAS:ARAV) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Aravive 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Aravive's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Aravive (Aravive) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (NAS:ARAV) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

VE11:Germany VE11:Germany

Address

3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098

Website

https://www.aravive.com

Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Executives

Maria Carolina Petrini	officer: Chief Commercial Officer	RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Robert B. Geller	officer: Chief Medical Officer	RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Rudy Howard	officer: Chief Financial Officer	322 WINDCHASE LANE, WILMINGTON NC 28409
Leonard Scott Dove	officer: Chief Operating Officer	RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Amato Giaccia	director, 10 percent owner	C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Gail Frances Mcintyre	officer: Chief Scientific Officer	C/O FURIEX PHARMACEUTICALS, INC., 3900 PARAMOUNT PARKWAY, SUITE 150, MORRISVILLE NC 27560
John Hohneker	director	C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Sigurd Kirk	director	225 SUMMIT AVENUE, MONTVALE NJ 07645
Peter Tai-ching Ho	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Vinay Shah	officer: Chief Financial Officer	C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Reshma Rangwala	officer: Chief Medical Officer	RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Michael W Rogers	director	C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Eshelman Ventures, Llc	director	319 N. 3RD STREET, SUITE 301, WILMINGTON NC 28401
Fredric N Eshelman	director	PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Rekha Hemrajani	director, officer: President and CEO	3928 POINT EDEN WAY, HAYWARD CA 94545